Delayed
Börse Stuttgart
|
5-day change
|
1st Jan Change
|
- EUR
|
-.--%
|
|
-2.31%
|
-53.99%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.185
|
1.12
|
7.143
|
0.5
|
6.2
|
1.5
|
EBITDA
1 |
-83.82
|
-88.77
|
-78.12
|
-52.61
|
-24.28
|
-26.97
|
EBIT
1 |
-87.39
|
-95.47
|
-85.3
|
-54.08
|
-24.39
|
-26.98
|
Operating Margin
|
-47,236.22%
|
-8,523.75%
|
-1,194.18%
|
-10,816.6%
|
-393.35%
|
-1,798.73%
|
Earnings before Tax (EBT)
1 |
-91.78
|
-98.04
|
-112.5
|
-7.722
|
-9.705
|
-24.97
|
Net income
1 |
-91.78
|
-98.04
|
-112.5
|
-7.722
|
-9.705
|
-24.97
|
Net margin
|
-49,610.27%
|
-8,753.21%
|
-1,574.65%
|
-1,544.4%
|
-156.53%
|
-1,664.87%
|
EPS
2 |
-28.94
|
-24.37
|
-24.01
|
-1.341
|
-0.8436
|
-0.8101
|
Free Cash Flow
1 |
-53.23
|
-38.4
|
8.89
|
-70.84
|
-27.87
|
-16.19
|
FCF margin
|
-28,775.61%
|
-3,428.81%
|
124.45%
|
-14,168.75%
|
-449.45%
|
-1,079.54%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/03/18
|
12/03/19
|
12/03/20
|
31/03/21
|
24/03/22
|
31/03/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
63.8
|
57
|
53
|
34.3
|
46.2
|
21.8
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-53.2
|
-38.4
|
8.89
|
-70.8
|
-27.9
|
-16.2
|
ROE (net income / shareholders' equity)
|
-101%
|
-128%
|
-353%
|
-143%
|
-33.5%
|
-79.9%
|
ROA (Net income/ Total Assets)
|
-40.8%
|
-46.4%
|
-44.8%
|
-43.1%
|
-34%
|
-46.2%
|
Assets
1 |
224.8
|
211.2
|
250.8
|
17.91
|
28.56
|
54.03
|
Book Value Per Share
2 |
25.40
|
15.70
|
-5.230
|
-0.3000
|
2.890
|
0.2300
|
Cash Flow per Share
2 |
11.70
|
10.00
|
18.20
|
4.270
|
5.480
|
2.530
|
Capex
1 |
12.1
|
1.62
|
0.52
|
0.63
|
0.01
|
0.02
|
Capex / Sales
|
6,558.92%
|
144.38%
|
7.31%
|
125%
|
0.11%
|
1.4%
|
Announcement Date
|
13/03/18
|
12/03/19
|
12/03/20
|
31/03/21
|
24/03/22
|
31/03/23
|
|
1st Jan change
|
Capi.
|
---|
| -53.99% | 822K | | +12.17% | 116B | | +12.56% | 106B | | -10.03% | 23.89B | | -1.69% | 21.58B | | -10.60% | 18.96B | | -41.25% | 16.96B | | -14.59% | 16.33B | | +6.18% | 14.14B | | +29.76% | 12.02B |
Bio Therapeutic Drugs
|